首页 > 最新文献

Pharmacology & Therapeutics最新文献

英文 中文
Cerebrovascular protective functions of amyloid precursor protein: Progress and therapeutic prospects 淀粉样前体蛋白的脑血管保护功能:研究进展及治疗前景。
IF 12.5 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2025-09-05 DOI: 10.1016/j.pharmthera.2025.108921
Zvonimir S. Katusic , Livius V. d'Uscio , Tongrong He
Under physiological conditions, amyloid precursor protein (APP) is critically important for normal brain development, neurogenesis, neuronal survival, and synaptic signaling. Dyshomeostasis of APP increases deposition and accumulation of amyloid β (Aβ) in the brain parenchyma and cerebral blood vessels thereby leading to development of Alzheimer's disease and cerebral amyloid angiopathy. In this review, we critically examine existing literature supporting the concept that endothelial APP performs important vascular protective functions in the brain. Studies in cultured human brain microvascular endothelium and cerebral arteries derived from genetically modified mice indicate that loss of APP impairs expression and function of Krüppel-like Factor 2 (KLF2) and endothelial nitric oxide synthase (eNOS) thereby causing endothelial dysfunction. Congruency between the findings obtained in murine and human cerebrovascular endothelium is consistent with strong evolutionary conservation of APP, and reinforces the concept that APP is an important vascular protective protein. Furthermore, we highlight vascular protective effects of APP during aging. We also address the roles of endothelial prostacyclin and nitric oxide in control of expression and proteolytic cleavage of APP. Finally, we outline potential translational opportunities emerging from recent advances in understanding of cerebrovascular function of APP. Several pharmacologically active domains of APP have been identified thus providing templates for creation of novel peptides with therapeutic properties.
在生理条件下,淀粉样蛋白前体蛋白(APP)对正常大脑发育、神经发生、神经元存活和突触信号传导至关重要。APP的失衡增加了脑实质和脑血管中β淀粉样蛋白(Aβ)的沉积和积累,从而导致阿尔茨海默病和脑淀粉样血管病的发展。在这篇综述中,我们对支持内皮APP在大脑中发挥重要血管保护功能的现有文献进行了批判性的研究。对培养的人脑微血管内皮和转基因小鼠脑动脉的研究表明,APP缺失会损害kr ppel样因子2 (KLF2)和内皮型一氧化氮合酶(eNOS)的表达和功能,从而导致内皮功能障碍。在小鼠和人类脑血管内皮中获得的结果的一致性与APP的强进化保守性一致,并加强了APP是一种重要的血管保护蛋白的概念。此外,我们强调了APP在衰老过程中的血管保护作用。我们还讨论了内皮细胞前列环素和一氧化氮在控制APP表达和蛋白水解裂解中的作用。最后,我们概述了APP脑血管功能的最新进展所带来的潜在翻译机会。已经确定了APP的几个药理活性结构域,从而为创造具有治疗特性的新型肽提供了模板。
{"title":"Cerebrovascular protective functions of amyloid precursor protein: Progress and therapeutic prospects","authors":"Zvonimir S. Katusic ,&nbsp;Livius V. d'Uscio ,&nbsp;Tongrong He","doi":"10.1016/j.pharmthera.2025.108921","DOIUrl":"10.1016/j.pharmthera.2025.108921","url":null,"abstract":"<div><div>Under physiological conditions, amyloid precursor protein (APP) is critically important for normal brain development, neurogenesis, neuronal survival, and synaptic signaling. Dyshomeostasis of APP increases deposition and accumulation of amyloid β (Aβ) in the brain parenchyma and cerebral blood vessels thereby leading to development of Alzheimer's disease and cerebral amyloid angiopathy. In this review, we critically examine existing literature supporting the concept that endothelial APP performs important vascular protective functions in the brain. Studies in cultured human brain microvascular endothelium and cerebral arteries derived from genetically modified mice indicate that loss of APP impairs expression and function of Krüppel-like Factor 2 (KLF2) and endothelial nitric oxide synthase (eNOS) thereby causing endothelial dysfunction. Congruency between the findings obtained in murine and human cerebrovascular endothelium is consistent with strong evolutionary conservation of APP, and reinforces the concept that APP is an important vascular protective protein. Furthermore, we highlight vascular protective effects of APP during aging. We also address the roles of endothelial prostacyclin and nitric oxide in control of expression and proteolytic cleavage of APP. Finally, we outline potential translational opportunities emerging from recent advances in understanding of cerebrovascular function of APP. Several pharmacologically active domains of APP have been identified thus providing templates for creation of novel peptides with therapeutic properties.</div></div>","PeriodicalId":402,"journal":{"name":"Pharmacology & Therapeutics","volume":"275 ","pages":"Article 108921"},"PeriodicalIF":12.5,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Air pollution and diseases: signaling, G protein-coupled and Toll like receptors 空气污染与疾病:信号、G蛋白偶联和Toll样受体。
IF 12.5 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2025-09-04 DOI: 10.1016/j.pharmthera.2025.108920
Isabella Cattani-Cavalieri , Katrina F. Ostrom , Jordyn Margolis , Rennolds S. Ostrom , Martina Schmidt
Air pollution is a significant public health issue that impacts lung health, particularly in vulnerable populations such as children, the elderly, and individuals with pre-existing respiratory conditions. Both natural and anthropogenic sources of air pollution give rise to a variety of toxic compounds, including particulate matter (PM), ozone (O₃), sulfur dioxide (SO₂), nitrogen dioxide (NO₂), carbon monoxide (CO), and polycyclic aromatic hydrocarbons (PAHs). Exposure to these pollutants is strongly associated with the development and exacerbation of respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), lung cancer, and idiopathic pulmonary fibrosis (IPF). Notably, early life exposure to pollutants such as PM, NO₂, and O₃ is linked to an increased risk of childhood asthma. Air pollution can mediate adverse effects through effects on receptor signaling pathways, particularly those involving G-protein coupled receptors (GPCRs) and Toll-like receptors (TLRs). Both of these receptor families play key roles in regulating pulmonary function and immune responses. GPCRs are involved in mediating cellular responses via cyclic AMP (cAMP), calcium and other second messengers, while TLRs initiate immune responses. Understanding how air pollutants and cigarette smoke alter GPCR and TLR function to contribute to lung disease is a critical area of study, as these receptors play central roles in regulating inflammation, immune responses, oxidative stress, airway remodeling and airway tone. Disruption of their signaling by pollutants can exacerbate respiratory conditions such as asthma and COPD. This review explores what is known about how air pollution impacts GPCR and TLR signaling, offers insights into the mechanisms underlying respiratory disease development and highlights potential therapeutic strategies aimed at mitigating the impact of air pollution on lung health.
空气污染是一个影响肺部健康的重大公共卫生问题,特别是在儿童、老年人和已有呼吸系统疾病的个人等脆弱人群中。自然和人为的空气污染源都会产生各种有毒化合物,包括颗粒物(PM)、臭氧(O₃)、二氧化硫(SO₂)、二氧化氮(NO₂)、一氧化碳(CO)和多环芳烃(PAHs)。暴露于这些污染物与呼吸系统疾病的发生和恶化密切相关,包括哮喘、慢性阻塞性肺疾病(COPD)、肺癌和特发性肺纤维化(IPF)。值得注意的是,幼年接触PM、NO₂、O₃等污染物与儿童哮喘的风险增加有关。空气污染可通过影响受体信号通路,特别是涉及g蛋白偶联受体(gpcr)和toll样受体(TLRs)的受体信号通路,介导不利影响。这两个受体家族在调节肺功能和免疫反应中发挥关键作用。gpcr通过环AMP (cAMP)、钙和其他第二信使参与介导细胞反应,而tlr则启动免疫反应。了解空气污染物和香烟烟雾如何改变GPCR和TLR功能从而导致肺部疾病是一个关键的研究领域,因为这些受体在调节炎症、免疫反应、氧化应激、气道重塑和气道张力方面发挥着核心作用。污染物对其信号的破坏会加剧哮喘和慢性阻塞性肺病等呼吸系统疾病。这篇综述探讨了空气污染如何影响GPCR和TLR信号传导的已知情况,为呼吸系统疾病发展的机制提供了见解,并强调了旨在减轻空气污染对肺部健康影响的潜在治疗策略。
{"title":"Air pollution and diseases: signaling, G protein-coupled and Toll like receptors","authors":"Isabella Cattani-Cavalieri ,&nbsp;Katrina F. Ostrom ,&nbsp;Jordyn Margolis ,&nbsp;Rennolds S. Ostrom ,&nbsp;Martina Schmidt","doi":"10.1016/j.pharmthera.2025.108920","DOIUrl":"10.1016/j.pharmthera.2025.108920","url":null,"abstract":"<div><div>Air pollution is a significant public health issue that impacts lung health, particularly in vulnerable populations such as children, the elderly, and individuals with pre-existing respiratory conditions. Both natural and anthropogenic sources of air pollution give rise to a variety of toxic compounds, including particulate matter (PM), ozone (O₃), sulfur dioxide (SO₂), nitrogen dioxide (NO₂), carbon monoxide (CO), and polycyclic aromatic hydrocarbons (PAHs). Exposure to these pollutants is strongly associated with the development and exacerbation of respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), lung cancer, and idiopathic pulmonary fibrosis (IPF). Notably, early life exposure to pollutants such as PM, NO₂, and O₃ is linked to an increased risk of childhood asthma. Air pollution can mediate adverse effects through effects on receptor signaling pathways, particularly those involving G-protein coupled receptors (GPCRs) and Toll-like receptors (TLRs). Both of these receptor families play key roles in regulating pulmonary function and immune responses. GPCRs are involved in mediating cellular responses via cyclic AMP (cAMP), calcium and other second messengers, while TLRs initiate immune responses. Understanding how air pollutants and cigarette smoke alter GPCR and TLR function to contribute to lung disease is a critical area of study, as these receptors play central roles in regulating inflammation, immune responses, oxidative stress, airway remodeling and airway tone. Disruption of their signaling by pollutants can exacerbate respiratory conditions such as asthma and COPD. This review explores what is known about how air pollution impacts GPCR and TLR signaling, offers insights into the mechanisms underlying respiratory disease development and highlights potential therapeutic strategies aimed at mitigating the impact of air pollution on lung health.</div></div>","PeriodicalId":402,"journal":{"name":"Pharmacology & Therapeutics","volume":"275 ","pages":"Article 108920"},"PeriodicalIF":12.5,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145007087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Suppressor tRNAs as personalized therapy for nonsense mutation-associated pathologies 抑制trna作为无义突变相关病理的个性化治疗
IF 12.5 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2025-08-22 DOI: 10.1016/j.pharmthera.2025.108919
Zoya Ignatova, Suki Albers
Nonsense mutations – associated with many devastating genetic disorders that currently lack effective treatments – prematurely terminate protein synthesis by converting an amino acid-encoding sense codon into a termination codon. Transfer RNAs (tRNAs), essential players in protein synthesis, have naturally evolved to decode sense codons, while avoiding the three stop codons (UGA, UAG, and UAA) that signal termination of translation. Emerging therapeutic strategies increasingly focus on refactoring natural tRNAs into suppressor tRNAs (sup-tRNAs). These engineered sup-tRNAs recognize nonsense mutation-associated premature stop codons (PTCs), restore translation, and recover protein function. This review summarizes recent advances in the design of sup-tRNAs to decode PTCs and discusses critical milestones in developing sup-tRNAs as a personalized therapeutic approach tailored to individual genetic backgrounds for treating pathologic conditions associated with nonsense mutations.
无义突变——与许多目前缺乏有效治疗的毁灭性遗传疾病相关——通过将编码氨基酸的意义密码子转化为终止密码子而过早终止蛋白质合成。转运rna (Transfer RNAs, trna)是蛋白质合成的重要参与者,自然进化为解码意义密码子,同时避免翻译终止的三个终止密码子(UGA, UAG和UAA)。新兴的治疗策略越来越关注于将天然trna重构为抑制trna (sup- trna)。这些工程化的超trna识别无义突变相关的过早终止密码子(ptc),恢复翻译并恢复蛋白质功能。这篇综述总结了解码ptc的suptrna设计的最新进展,并讨论了发展suptrna作为针对个体遗传背景的个性化治疗方法来治疗与无义突变相关的病理状况的关键里程碑。
{"title":"Suppressor tRNAs as personalized therapy for nonsense mutation-associated pathologies","authors":"Zoya Ignatova,&nbsp;Suki Albers","doi":"10.1016/j.pharmthera.2025.108919","DOIUrl":"10.1016/j.pharmthera.2025.108919","url":null,"abstract":"<div><div>Nonsense mutations – associated with many devastating genetic disorders that currently lack effective treatments – prematurely terminate protein synthesis by converting an amino acid-encoding sense codon into a termination codon. Transfer RNAs (tRNAs), essential players in protein synthesis, have naturally evolved to decode sense codons, while avoiding the three stop codons (UGA, UAG, and UAA) that signal termination of translation. Emerging therapeutic strategies increasingly focus on refactoring natural tRNAs into suppressor tRNAs (sup-tRNAs). These engineered sup-tRNAs recognize nonsense mutation-associated premature stop codons (PTCs), restore translation, and recover protein function. This review summarizes recent advances in the design of sup-tRNAs to decode PTCs and discusses critical milestones in developing sup-tRNAs as a personalized therapeutic approach tailored to individual genetic backgrounds for treating pathologic conditions associated with nonsense mutations.</div></div>","PeriodicalId":402,"journal":{"name":"Pharmacology & Therapeutics","volume":"274 ","pages":"Article 108919"},"PeriodicalIF":12.5,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144906906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic exploration of biased ligands at class A G protein-coupled receptors over the past 20 years 在过去的20年中,对A类G蛋白偶联受体的偏配体的治疗探索
IF 12.5 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2025-08-21 DOI: 10.1016/j.pharmthera.2025.108918
Jixia Wang , Fangfang Xu , Yanfang Liu , Han Zhou , Wenjie Yuan , Fan Liu , Ye Fang , Xinmiao Liang
Recent decades have witnessed significant advances in the development of biased ligands for G protein-coupled receptors (GPCRs) as potential therapeutic agents with enhanced efficacy and reduced on-target side effects. This is largely attributed to the unique capability of biased ligands to activate pathway-selective signaling, which can effectively modulate in vivo pharmacology. This review presents a comprehensive analysis of biased ligands targeting class A GPCRs over the past 20 years, encompassing discovery strategies, assays, biological effects and therapeutic applications. The analysis covers approximately 383 biased ligands acting on 60 different GPCRs, among which opioid, 5-hydroxytryptamine, dopamine, adrenergic and cannabinoid receptors are the five subfamilies with the highest number of reported biased ligands. The biological effects of these biased ligands are primarily investigated in the area of pain, cardiovascular, neurological, respiratory, metabolic and inflammatory diseases. The regulatory approval of the opioid biased agonist TRV130 for pain management, along with the growing number of biased drugs tested in clinical trials, heralds a new era in GPCR drug development. Additionally, various natural product biased ligands have been identified. A deeper understanding of the biological functions and pharmacological effects of biased ligands will support future advancements in GPCR drug development.
近几十年来,G蛋白偶联受体(gpcr)的偏配体的发展取得了重大进展,作为潜在的治疗药物,具有增强的疗效和减少靶侧副作用。这在很大程度上归因于偏配体激活途径选择性信号传导的独特能力,这可以有效地调节体内药理学。本文综述了过去20年来针对a类gpcr的偏配体的综合分析,包括发现策略,分析,生物学效应和治疗应用。该分析涵盖了作用于60种不同gpcr的约383种偏置配体,其中阿片受体、5-羟色胺受体、多巴胺受体、肾上腺素能受体和大麻素受体是报道偏置配体数量最多的五个亚家族。这些偏配体的生物学效应主要在疼痛、心血管、神经、呼吸、代谢和炎症疾病领域进行研究。阿片类药物偏倚激动剂TRV130被批准用于疼痛治疗,以及越来越多的偏倚药物在临床试验中进行测试,预示着GPCR药物开发的新时代。此外,各种天然产物偏置配体已被确定。更深入地了解偏配体的生物学功能和药理作用将支持未来GPCR药物开发的进展。
{"title":"Therapeutic exploration of biased ligands at class A G protein-coupled receptors over the past 20 years","authors":"Jixia Wang ,&nbsp;Fangfang Xu ,&nbsp;Yanfang Liu ,&nbsp;Han Zhou ,&nbsp;Wenjie Yuan ,&nbsp;Fan Liu ,&nbsp;Ye Fang ,&nbsp;Xinmiao Liang","doi":"10.1016/j.pharmthera.2025.108918","DOIUrl":"10.1016/j.pharmthera.2025.108918","url":null,"abstract":"<div><div>Recent decades have witnessed significant advances in the development of biased ligands for G protein-coupled receptors (GPCRs) as potential therapeutic agents with enhanced efficacy and reduced on-target side effects. This is largely attributed to the unique capability of biased ligands to activate pathway-selective signaling, which can effectively modulate in vivo pharmacology. This review presents a comprehensive analysis of biased ligands targeting class A GPCRs over the past 20 years, encompassing discovery strategies, assays, biological effects and therapeutic applications. The analysis covers approximately 383 biased ligands acting on 60 different GPCRs, among which opioid, 5-hydroxytryptamine, dopamine, adrenergic and cannabinoid receptors are the five subfamilies with the highest number of reported biased ligands. The biological effects of these biased ligands are primarily investigated in the area of pain, cardiovascular, neurological, respiratory, metabolic and inflammatory diseases. The regulatory approval of the opioid biased agonist TRV130 for pain management, along with the growing number of biased drugs tested in clinical trials, heralds a new era in GPCR drug development. Additionally, various natural product biased ligands have been identified. A deeper understanding of the biological functions and pharmacological effects of biased ligands will support future advancements in GPCR drug development.</div></div>","PeriodicalId":402,"journal":{"name":"Pharmacology & Therapeutics","volume":"274 ","pages":"Article 108918"},"PeriodicalIF":12.5,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144891968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neutrophil Extracellular Traps (NETs) as drivers of atherosclerosis: Pathogenic mechanisms and therapeutic opportunities 中性粒细胞胞外陷阱(NETs)作为动脉粥样硬化的驱动因素:致病机制和治疗机会
IF 12.5 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2025-08-20 DOI: 10.1016/j.pharmthera.2025.108917
Shravya Shetty , Manikandan Subramanian
Cardiovascular diseases (CVDs) are the leading cause of death globally. The primary pathological process underlying CVDs is atherosclerosis, a chronic lipid-driven inflammatory condition that results in the narrowing of medium- and large-arteries due to a build-up of fibrofatty, leukocyte-rich plaques. Adverse clinical outcomes are usually a result of plaque erosion or rupture which result in acute luminal thrombosis with ensuing tissue ischaemia. Immune cell infiltration and the associated inflammation are recognized as key drivers of the development of unstable plaques. Whilst the role of macrophages, dendritic cells, T- and B-lymphocytes are extensively documented in the progression of atherosclerosis, the role of neutrophils, which are the dominant leukocyte subset in humans, is relatively understudied. Interestingly, studies in the last decade have shed light on the critical role of neutrophil extracellular traps (NETs) in mediating inflammasome activation, plaque progression, and adverse clinical outcomes. NETs are complex extracellular DNA structures released by neutrophils undergoing death by a specialized process of NETosis. This review will comprehensively examine the key drivers of NETosis in atherosclerosis, mechanisms of NET clearance, the pathogenic role of NETs in plaque progression, and finally novel pharmacological approaches to target NETs to prevent atherothrombosis and its associated clinical complications.
心血管疾病是全球死亡的主要原因。心血管疾病的主要病理过程是动脉粥样硬化,这是一种慢性脂质驱动的炎症,由于纤维脂肪和富含白细胞的斑块的积聚,导致中大动脉狭窄。不良的临床结果通常是由于斑块侵蚀或破裂导致急性腔内血栓形成和随后的组织缺血。免疫细胞浸润和相关炎症被认为是不稳定斑块形成的关键驱动因素。虽然巨噬细胞、树突状细胞、T淋巴细胞和b淋巴细胞在动脉粥样硬化进展中的作用被广泛记载,但中性粒细胞(人类白细胞的主要亚群)的作用却相对缺乏研究。有趣的是,过去十年的研究揭示了中性粒细胞胞外陷阱(NETs)在介导炎性体激活、斑块进展和不良临床结果中的关键作用。net是一种复杂的细胞外DNA结构,由中性粒细胞在死亡过程中通过NETosis的特殊过程释放。本文将全面探讨动脉粥样硬化中NETosis的关键驱动因素,NET清除的机制,NET在斑块进展中的致病作用,以及针对NET预防动脉粥样硬化血栓形成及其相关临床并发症的新药理学方法。
{"title":"Neutrophil Extracellular Traps (NETs) as drivers of atherosclerosis: Pathogenic mechanisms and therapeutic opportunities","authors":"Shravya Shetty ,&nbsp;Manikandan Subramanian","doi":"10.1016/j.pharmthera.2025.108917","DOIUrl":"10.1016/j.pharmthera.2025.108917","url":null,"abstract":"<div><div>Cardiovascular diseases (CVDs) are the leading cause of death globally. The primary pathological process underlying CVDs is atherosclerosis, a chronic lipid-driven inflammatory condition that results in the narrowing of medium- and large-arteries due to a build-up of fibrofatty, leukocyte-rich plaques. Adverse clinical outcomes are usually a result of plaque erosion or rupture which result in acute luminal thrombosis with ensuing tissue ischaemia. Immune cell infiltration and the associated inflammation are recognized as key drivers of the development of unstable plaques. Whilst the role of macrophages, dendritic cells, T- and B-lymphocytes are extensively documented in the progression of atherosclerosis, the role of neutrophils, which are the dominant leukocyte subset in humans, is relatively understudied. Interestingly, studies in the last decade have shed light on the critical role of neutrophil extracellular traps (NETs) in mediating inflammasome activation, plaque progression, and adverse clinical outcomes. NETs are complex extracellular DNA structures released by neutrophils undergoing death by a specialized process of NETosis. This review will comprehensively examine the key drivers of NETosis in atherosclerosis, mechanisms of NET clearance, the pathogenic role of NETs in plaque progression, and finally novel pharmacological approaches to target NETs to prevent atherothrombosis and its associated clinical complications.</div></div>","PeriodicalId":402,"journal":{"name":"Pharmacology & Therapeutics","volume":"274 ","pages":"Article 108917"},"PeriodicalIF":12.5,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144886277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Macrophages at the crossroads of cellular senescence and cancer development and progression: Therapeutic opportunities and challenges 巨噬细胞在细胞衰老和癌症发展和进展的十字路口:治疗的机遇和挑战。
IF 12.5 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2025-08-07 DOI: 10.1016/j.pharmthera.2025.108906
Shi-Long Jiang , Dong Wang , Chan Zou , Ze-Wu Zhu , Chao Luo , Zhi-Bin Wang
Macrophages are pleiotropic immune cells essential for maintaining tissue homeostasis and modulating immune responses. Their inherent plasticity enables polarization into distinct functional phenotypes: M1 (pro-inflammatory) and M2 (anti-inflammatory), which critically influence the progression of various diseases, including cancer. Cellular senescence, a state characterized by irreversible cell cycle arrest and the secretion of pro-inflammatory factors (SASP), substantially contributes to aging and disease pathogenesis. The interaction between macrophages and senescent cells is complex: macrophages contribute to tissue integrity by clearing senescent cells to prevent tissue dysfunction, while senescent cells can alter macrophage function, influencing inflammation and cancer development. This review examines the dual roles of macrophages in cellular senescence and cancer, focusing on their capacity to both protect against and promote tumor progression. It examines how macrophages recognize and phagocytose senescent cells, the impact of macrophage dysfunction on senescence-associated pathologies, and the role of tumor-associated macrophages (TAMs) in shaping the tumor microenvironment. Key concepts to be addressed include macrophage plasticity, SASP-mediated modulation of macrophage function, and the dual role of macrophages in cancer, where they can either suppress tumor growth or promote progression via angiogenesis, immune evasion, and metastasis. The mutual interplay between macrophages and senescent cells highlights the therapeutic potential of targeting this interaction for managing age-related diseases and cancer.
巨噬细胞是维持组织稳态和调节免疫反应所必需的多效免疫细胞。它们固有的可塑性使其分化为不同的功能表型:M1(促炎)和M2(抗炎),这对包括癌症在内的各种疾病的进展具有关键影响。细胞衰老是一种以不可逆的细胞周期停滞和促炎因子(SASP)分泌为特征的状态,在很大程度上有助于衰老和疾病的发病。巨噬细胞与衰老细胞之间的相互作用是复杂的:巨噬细胞通过清除衰老细胞以防止组织功能障碍来促进组织完整性,而衰老细胞可以改变巨噬细胞的功能,影响炎症和癌症的发展。本文综述了巨噬细胞在细胞衰老和癌症中的双重作用,重点介绍了它们预防和促进肿瘤进展的能力。它探讨了巨噬细胞如何识别和吞噬衰老细胞,巨噬细胞功能障碍对衰老相关病理的影响,以及肿瘤相关巨噬细胞(tam)在塑造肿瘤微环境中的作用。需要解决的关键概念包括巨噬细胞的可塑性、sasp介导的巨噬细胞功能调节,以及巨噬细胞在癌症中的双重作用,它们可以抑制肿瘤生长或通过血管生成、免疫逃避和转移促进肿瘤进展。巨噬细胞和衰老细胞之间的相互作用突出了针对这种相互作用治疗年龄相关疾病和癌症的治疗潜力。
{"title":"Macrophages at the crossroads of cellular senescence and cancer development and progression: Therapeutic opportunities and challenges","authors":"Shi-Long Jiang ,&nbsp;Dong Wang ,&nbsp;Chan Zou ,&nbsp;Ze-Wu Zhu ,&nbsp;Chao Luo ,&nbsp;Zhi-Bin Wang","doi":"10.1016/j.pharmthera.2025.108906","DOIUrl":"10.1016/j.pharmthera.2025.108906","url":null,"abstract":"<div><div>Macrophages are pleiotropic immune cells essential for maintaining tissue homeostasis and modulating immune responses. Their inherent plasticity enables polarization into distinct functional phenotypes: M1 (pro-inflammatory) and M2 (anti-inflammatory), which critically influence the progression of various diseases, including cancer. Cellular senescence, a state characterized by irreversible cell cycle arrest and the secretion of pro-inflammatory factors (SASP), substantially contributes to aging and disease pathogenesis. The interaction between macrophages and senescent cells is complex: macrophages contribute to tissue integrity by clearing senescent cells to prevent tissue dysfunction, while senescent cells can alter macrophage function, influencing inflammation and cancer development. This review examines the dual roles of macrophages in cellular senescence and cancer, focusing on their capacity to both protect against and promote tumor progression. It examines how macrophages recognize and phagocytose senescent cells, the impact of macrophage dysfunction on senescence-associated pathologies, and the role of tumor-associated macrophages (TAMs) in shaping the tumor microenvironment. Key concepts to be addressed include macrophage plasticity, SASP-mediated modulation of macrophage function, and the dual role of macrophages in cancer, where they can either suppress tumor growth or promote progression via angiogenesis, immune evasion, and metastasis. The mutual interplay between macrophages and senescent cells highlights the therapeutic potential of targeting this interaction for managing age-related diseases and cancer.</div></div>","PeriodicalId":402,"journal":{"name":"Pharmacology & Therapeutics","volume":"274 ","pages":"Article 108906"},"PeriodicalIF":12.5,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144805707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of lysine acetylation in metabolic sensing and proteostasis 赖氨酸乙酰化在代谢感知和蛋白质静止中的作用。
IF 12.5 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2025-08-07 DOI: 10.1016/j.pharmthera.2025.108908
Aziz Eftekhari , Usman Sabir , Takhar Kasumov
Post-translational acetylation of lysine residues is a dynamic and reversible modification that plays a pivotal role in regulating protein structure, function, and interactions. This modification is mediated by central metabolite acetyl-CoA and is tightly controlled by the opposing actions of lysine acetyltransferases (KATs) and lysine deacetylases (KDACs), including the NAD+-dependent sirtuins. As a nutrient-sensing post-translational modification (PTM), acetylation is essential for maintaining cellular homeostasis, particularly by modulating proteostasis and metabolic flexibility—the ability of cells to rewire metabolic pathways in response to fluctuating energy demands and nutrient availability.
Dysregulation of acetylation has been implicated in the pathogenesis of metabolic disorders, neurodegenerative diseases, and cancer. Emerging evidence suggests that targeting acetylation-regulating enzymes with small-molecule inhibitors or activators hold promise for elucidating the role of acetylation in metabolic sensing and protein homeostasis. This review examines the regulation of acetylation across various metabolic states, its impact on metabolic adaptability, and its intricate interplay with proteostasis mechanisms. Additionally, it highlights the role of site-specific acetylation dynamics and sirtuin biology shaping metabolic regulation, providing key insights into the mechanisms underlying metabolic disorders and their progression. Understanding the regulatory mechanisms governing acetylation-dependent metabolic sensing could facilitate the development of precision therapeutics to restore metabolic homeostasis.
赖氨酸残基的翻译后乙酰化是一种动态可逆的修饰,在调节蛋白质结构、功能和相互作用中起着关键作用。这种修饰是由中心代谢物乙酰辅酶a介导的,并受到赖氨酸乙酰转移酶(KATs)和赖氨酸去乙酰化酶(kdac)的相反作用的严格控制,包括NAD+依赖性sirtuins。作为一种营养感应翻译后修饰(PTM),乙酰化对于维持细胞内稳态至关重要,特别是通过调节蛋白质稳态和代谢灵活性——细胞在能量需求和营养可用性波动时重新连接代谢途径的能力。乙酰化的失调与代谢紊乱、神经退行性疾病和癌症的发病机制有关。新出现的证据表明,用小分子抑制剂或激活剂靶向乙酰化调节酶有望阐明乙酰化在代谢传感和蛋白质稳态(也称为蛋白质稳态)中的作用。本文综述了乙酰化在不同代谢状态下的调控,其对代谢适应性的影响,以及其与蛋白质平衡机制的复杂相互作用。此外,它还强调了位点特异性乙酰化动力学和sirtuin生物学对代谢调节的作用,为代谢紊乱及其进展的机制提供了关键见解。了解乙酰化依赖性代谢感知的调控机制可以促进精确治疗的发展,以恢复代谢稳态。
{"title":"The role of lysine acetylation in metabolic sensing and proteostasis","authors":"Aziz Eftekhari ,&nbsp;Usman Sabir ,&nbsp;Takhar Kasumov","doi":"10.1016/j.pharmthera.2025.108908","DOIUrl":"10.1016/j.pharmthera.2025.108908","url":null,"abstract":"<div><div>Post-translational acetylation of lysine residues is a dynamic and reversible modification that plays a pivotal role in regulating protein structure, function, and interactions. This modification is mediated by central metabolite acetyl-CoA and is tightly controlled by the opposing actions of lysine acetyltransferases (<strong>KAT</strong>s) and lysine deacetylases (<strong>KDAC</strong>s), including the NAD<sup>+</sup>-dependent sirtuins. As a nutrient-sensing post-translational modification (<strong>PTM</strong>), acetylation is essential for maintaining cellular homeostasis, particularly by modulating proteostasis and metabolic flexibility—the ability of cells to rewire metabolic pathways in response to fluctuating energy demands and nutrient availability.</div><div>Dysregulation of acetylation has been implicated in the pathogenesis of metabolic disorders, neurodegenerative diseases, and cancer. Emerging evidence suggests that targeting acetylation-regulating enzymes with small-molecule inhibitors or activators hold promise for elucidating the role of acetylation in metabolic sensing and protein homeostasis. This review examines the regulation of acetylation across various metabolic states, its impact on metabolic adaptability, and its intricate interplay with proteostasis mechanisms. Additionally, it highlights the role of site-specific acetylation dynamics and sirtuin biology shaping metabolic regulation, providing key insights into the mechanisms underlying metabolic disorders and their progression. Understanding the regulatory mechanisms governing acetylation-dependent metabolic sensing could facilitate the development of precision therapeutics to restore metabolic homeostasis.</div></div>","PeriodicalId":402,"journal":{"name":"Pharmacology & Therapeutics","volume":"274 ","pages":"Article 108908"},"PeriodicalIF":12.5,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144805704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of G protein-coupled receptor conformation on signaling bias: Integrating simulations and biophysical experiments G蛋白偶联受体构象对信号偏倚的影响:整合模拟和生物物理实验。
IF 12.5 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2025-08-07 DOI: 10.1016/j.pharmthera.2025.108905
Gian Marco Elisi , Giovanni Bottegoni
G protein-coupled receptors (GPCRs) are a ubiquitous family of transmembrane proteins essential for signal transduction and serve as key targets for numerous drug classes. A single GPCR often mediates multiple, largely independent pathways, which can sometimes be selectively modulated by biased ligands that preferentially activate specific signaling routes. These molecules stabilize distinct receptor conformations, with even subtle structural variations capable of driving different cellular responses. Capturing the conformations responsible for biased signaling, however, often proves challenging with traditional experimental techniques. Recent advances in experimental methods, coupled with computational modeling, have shed new light on the structural mechanisms underlying biased signaling. This review highlights therapeutically relevant examples, focusing on mechanisms such as (i) partial occupation of the orthosteric pocket, resulting in submaximal activation, and (ii) binding to alternative sites via bitopic or allosteric compounds. Emphasis is placed on studies that integrate biophysical and computational approaches, demonstrating their synergistic potential to unravel the complexities of GPCR signaling. This combined strategy paves the way for the rational design of innovative drugs with greater precision and therapeutic efficacy.
G蛋白偶联受体(gpcr)是一个普遍存在的跨膜蛋白家族,对信号转导至关重要,是许多药物类别的关键靶点。单个GPCR通常介导多个基本独立的通路,有时可以通过优先激活特定信号通路的偏配体选择性调节。这些分子稳定了不同的受体构象,即使是细微的结构变化也能驱动不同的细胞反应。然而,传统的实验技术往往证明捕获负责偏置信号的构象具有挑战性。实验方法的最新进展,加上计算模型,揭示了偏置信号的结构机制。这篇综述强调了与治疗相关的例子,重点是机制,如(i)部分占据矫形口袋,导致亚最大激活,以及(ii)通过双取向或变构化合物与替代位点结合。重点放在整合生物物理和计算方法的研究上,展示了它们在解开GPCR信号复杂性方面的协同潜力。这种组合策略为创新药物的合理设计铺平了道路,具有更高的精度和治疗效果。
{"title":"Impact of G protein-coupled receptor conformation on signaling bias: Integrating simulations and biophysical experiments","authors":"Gian Marco Elisi ,&nbsp;Giovanni Bottegoni","doi":"10.1016/j.pharmthera.2025.108905","DOIUrl":"10.1016/j.pharmthera.2025.108905","url":null,"abstract":"<div><div>G protein-coupled receptors (GPCRs) are a ubiquitous family of transmembrane proteins essential for signal transduction and serve as key targets for numerous drug classes. A single GPCR often mediates multiple, largely independent pathways, which can sometimes be selectively modulated by biased ligands that preferentially activate specific signaling routes. These molecules stabilize distinct receptor conformations, with even subtle structural variations capable of driving different cellular responses. Capturing the conformations responsible for biased signaling, however, often proves challenging with traditional experimental techniques. Recent advances in experimental methods, coupled with computational modeling, have shed new light on the structural mechanisms underlying biased signaling. This review highlights therapeutically relevant examples, focusing on mechanisms such as (i) partial occupation of the orthosteric pocket, resulting in submaximal activation, and (ii) binding to alternative sites via bitopic or allosteric compounds. Emphasis is placed on studies that integrate biophysical and computational approaches, demonstrating their synergistic potential to unravel the complexities of GPCR signaling. This combined strategy paves the way for the rational design of innovative drugs with greater precision and therapeutic efficacy.</div></div>","PeriodicalId":402,"journal":{"name":"Pharmacology & Therapeutics","volume":"274 ","pages":"Article 108905"},"PeriodicalIF":12.5,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144805708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Human PSC-derived liver cells and their applications for disease models and drug discovery 人psc来源的肝细胞及其在疾病模型和药物发现中的应用。
IF 12.5 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2025-08-07 DOI: 10.1016/j.pharmthera.2025.108907
Yuta Koui , Minoru Tanaka , Taketomo Kido
The liver comprises hepatic parenchymal cells, primarily hepatocytes, and non-parenchymal cells such as liver sinusoidal endothelial cells (LSECs), hepatic stellate cells (HSCs), and cholangiocytes. These cell types interact with each other to maintain homeostasis through metabolism, detoxification, and protein synthesis. Such cellular interactions also play crucial roles in regulating the onset and progression of liver diseases. Consequently, the development of in vitro multicellular liver models is vital for elucidating the mechanisms underlying liver diseases and for evaluating the efficacy and toxicity of novel therapeutic drugs. Given their ability to proliferate and differentiate into diverse cell types in vitro, human pluripotent stem cells (hPSCs), including embryonic stem cells and induced PSCs, offer valuable potential for generating various liver cell types and constructing liver disease models for drug discovery research. Furthermore, patient-derived or gene-edited iPSCs can be employed to model genetic liver disorders. This review summarizes the development of differentiation protocols for hPSC-derived hepatocytes, LSECs, HSCs, and cholangiocytes, as well as their applications in drug discovery research.
肝脏包括肝实质细胞,主要是肝细胞和非实质细胞,如肝窦内皮细胞(LSECs)、肝星状细胞(hsc)和胆管细胞。这些细胞类型相互作用,通过代谢、解毒和蛋白质合成来维持体内平衡。这种细胞相互作用在调节肝脏疾病的发生和发展中也起着至关重要的作用。因此,体外多细胞肝脏模型的发展对于阐明肝脏疾病的机制以及评估新型治疗药物的疗效和毒性至关重要。人类多能干细胞(human pluripotent stem cells, hPSCs),包括胚胎干细胞和诱导多能干细胞,在体外具有增殖和分化为多种细胞类型的能力,为产生多种肝细胞类型和构建用于药物发现研究的肝病模型提供了宝贵的潜力。此外,患者衍生或基因编辑的iPSCs可用于遗传性肝脏疾病的建模。本文综述了造血干细胞来源的肝细胞、LSECs、造血干细胞和胆管细胞分化方案的发展及其在药物发现研究中的应用。
{"title":"Human PSC-derived liver cells and their applications for disease models and drug discovery","authors":"Yuta Koui ,&nbsp;Minoru Tanaka ,&nbsp;Taketomo Kido","doi":"10.1016/j.pharmthera.2025.108907","DOIUrl":"10.1016/j.pharmthera.2025.108907","url":null,"abstract":"<div><div>The liver comprises hepatic parenchymal cells, primarily hepatocytes, and non-parenchymal cells such as liver sinusoidal endothelial cells (LSECs), hepatic stellate cells (HSCs), and cholangiocytes. These cell types interact with each other to maintain homeostasis through metabolism, detoxification, and protein synthesis. Such cellular interactions also play crucial roles in regulating the onset and progression of liver diseases. Consequently, the development of <em>in vitro</em> multicellular liver models is vital for elucidating the mechanisms underlying liver diseases and for evaluating the efficacy and toxicity of novel therapeutic drugs. Given their ability to proliferate and differentiate into diverse cell types <em>in vitro</em>, human pluripotent stem cells (hPSCs), including embryonic stem cells and induced PSCs, offer valuable potential for generating various liver cell types and constructing liver disease models for drug discovery research. Furthermore, patient-derived or gene-edited iPSCs can be employed to model genetic liver disorders. This review summarizes the development of differentiation protocols for hPSC-derived hepatocytes, LSECs, HSCs, and cholangiocytes, as well as their applications in drug discovery research.</div></div>","PeriodicalId":402,"journal":{"name":"Pharmacology & Therapeutics","volume":"274 ","pages":"Article 108907"},"PeriodicalIF":12.5,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144805706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hydroxyl carboxylic acid receptor-2 (HCAR2) as a potential target in neurometabolic diseases 羟基羧酸受体2 (HCAR2)作为神经代谢性疾病的潜在靶点。
IF 12.5 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2025-08-07 DOI: 10.1016/j.pharmthera.2025.108909
Lara Testai , Francesca Guida , Silvia Salerno , Simone Brogi , Andrea Maria Morace , Leonardo Carbonetti , Federica Ricciardi , Michela Perrone , Enza Palazzo , Vincenzo Calderone , Sabatino Maione , Livio Luongo
Hydroxycarboxylic acid receptor 2 (HCAR2) is a G-protein-coupled receptor initially identified for its role in lipid metabolism. Beyond its classical metabolic functions, HCAR2 plays a pivotal role in chronic inflammatory diseases, neurometabolic disorders, and pain modulation. Evidence from preclinical studies suggest that when endogenously activated by β-hydroxybutyrate and pharmacologically by niacin and its derivatives, HCAR2 attenuates microglial reactivity, suppress pro-inflammatory cytokine release, and modulate neuronal excitability, by offering neuroprotective benefits in neurological disorders and chronic pain. Additionally, emerging data highlight its involvement in gut-brain axis regulation, linking dietary interventions and microbiota-derived metabolites to Central Nervous System function. The development of selective HCAR2 agonists with improved pharmacokinetic and safety profiles holds promise for treatments targeting both peripheral and central pathologies. This review explores the structural and functional aspects of HCAR2, and describe novel synthetic HCAR2 agonists, by emphasizing its therapeutic potential across a spectrum of metabolic and neuroinflammatory disorders.
羟基羧酸受体2 (HCAR2)是一种g蛋白偶联受体,最初因其在脂质代谢中的作用而被发现。除了经典的代谢功能外,HCAR2在慢性炎症疾病、神经代谢紊乱和疼痛调节中也起着关键作用。来自临床前研究的证据表明,当内源性由β-羟基丁酸和药理学上由烟酸及其衍生物激活时,HCAR2通过在神经系统疾病和慢性疼痛中提供神经保护作用,减弱小胶质细胞的反应性,抑制促炎细胞因子的释放,调节神经元的兴奋性。此外,新出现的数据强调其参与肠-脑轴调节,将饮食干预和微生物衍生代谢物与中枢神经系统功能联系起来。具有改善药代动力学和安全性的选择性HCAR2激动剂的发展为针对周围和中枢病变的治疗带来了希望。这篇综述探讨了HCAR2的结构和功能方面,并通过强调其在代谢和神经炎症疾病中的治疗潜力,描述了新的合成HCAR2激动剂。
{"title":"Hydroxyl carboxylic acid receptor-2 (HCAR2) as a potential target in neurometabolic diseases","authors":"Lara Testai ,&nbsp;Francesca Guida ,&nbsp;Silvia Salerno ,&nbsp;Simone Brogi ,&nbsp;Andrea Maria Morace ,&nbsp;Leonardo Carbonetti ,&nbsp;Federica Ricciardi ,&nbsp;Michela Perrone ,&nbsp;Enza Palazzo ,&nbsp;Vincenzo Calderone ,&nbsp;Sabatino Maione ,&nbsp;Livio Luongo","doi":"10.1016/j.pharmthera.2025.108909","DOIUrl":"10.1016/j.pharmthera.2025.108909","url":null,"abstract":"<div><div>Hydroxycarboxylic acid receptor 2 (HCAR2) is a G-protein-coupled receptor initially identified for its role in lipid metabolism. Beyond its classical metabolic functions, HCAR2 plays a pivotal role in chronic inflammatory diseases, neurometabolic disorders, and pain modulation. Evidence from preclinical studies suggest that when endogenously activated by β-hydroxybutyrate and pharmacologically by niacin and its derivatives, HCAR2 attenuates microglial reactivity, suppress pro-inflammatory cytokine release, and modulate neuronal excitability, by offering neuroprotective benefits in neurological disorders and chronic pain. Additionally, emerging data highlight its involvement in gut-brain axis regulation, linking dietary interventions and microbiota-derived metabolites to Central Nervous System function. The development of selective HCAR2 agonists with improved pharmacokinetic and safety profiles holds promise for treatments targeting both peripheral and central pathologies. This review explores the structural and functional aspects of HCAR2, and describe novel synthetic HCAR2 agonists, by emphasizing its therapeutic potential across a spectrum of metabolic and neuroinflammatory disorders.</div></div>","PeriodicalId":402,"journal":{"name":"Pharmacology & Therapeutics","volume":"274 ","pages":"Article 108909"},"PeriodicalIF":12.5,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144805705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Pharmacology & Therapeutics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1